Taysha Gene Therapies, Inc.
TSHA
$1.24
$0.065.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 26.40% | -21.96% | 13.02% | -150.40% | 140.77% |
| Total Depreciation and Amortization | 3.40% | -8.70% | -0.92% | -11.20% | 10.57% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.79% | 180.64% | -7.03% | 106.04% | -156.74% |
| Change in Net Operating Assets | 55.78% | -37.37% | -1,536.91% | 106.15% | 34.23% |
| Cash from Operations | 15.30% | -0.52% | -8.62% | -22.84% | 10.21% |
| Capital Expenditure | 105.71% | 82.59% | -43.57% | -723.53% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 100.20% |
| Cash from Investing | 137.14% | 82.59% | -43.57% | -1,300.00% | 99.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -90.46% | 270,980.77% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 102.36% | -876.92% | 72.92% | 87.20% | -286.60% |
| Cash from Financing | -105.41% | -90.64% | 320,409.09% | 99.48% | -103.02% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -23.89% | -130.87% | 344.30% | 2.04% | -117.09% |